SuperworthAnika Therapeutics EPS ANIK
Diluted earnings per share by quarter and over the last twelve months, from 2010.
- Last 12 months, to Jun 30, 2026
- −$0.27
- Latest quarter, Q2 FY26
- $0.24
- Fiscal year 2025
- −$0.76
Anika Therapeutics' earnings per share was −$0.27 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was $0.24.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$0.76 | n/a |
| FY2024 | −$3.84 | n/a |
| FY2023 | −$5.65 | n/a |
| FY2022 | −$1.03 | −455% |
| FY2021 | $0.29 | n/a |
| FY2020 | −$1.69 | −189% |
| FY2019 | $1.90 | +47% |
| FY2018 | $1.29 | −39% |
| FY2017 | $2.12 | −1% |
| FY2016 | $2.15 | +7% |
| FY2015 | $2.01 | −19% |
| FY2014 | $2.48 | +80% |
| FY2013 | $1.38 | +68% |
| FY2012 | $0.82 | +32% |
| FY2011 | $0.62 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $0.24 | n/a | −$0.27 | |
| Q1 FY26 | −$0.37 | n/a | −$0.79 | |
| Q4 FY25 | $0.02 | n/a | −$0.76 | |
| Q3 FY25 | −$0.16 | n/a | −$2.28 | |
| Q2 FY25 | −$0.28 | n/a | −$4.15 | |
| Q1 FY25 | −$0.34 | n/a | −$3.87 | |
| Q4 FY24 | −$1.50 | n/a | −$3.84 | |
| Q3 FY24 | −$2.03 | n/a | −$6.64 | |
| Q2 FY24 | $0.00 | n/a | −$5.06 | |
| Q1 FY24 | −$0.31 | n/a | −$5.25 | |
| Q4 FY23 | −$4.30 | n/a | −$5.65 | |
| Q3 FY23 | −$0.45 | n/a | −$1.69 |
Against its peers
Companies in Medical - Instruments & Supplies nearest Anika Therapeutics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| ANIKAnika Therapeutics | −$0.27 | |
| INFUInfuSystem | $0.41 | +78% a year |
| UTMDUtah Medical Products | $3.28 | −12% a year |
| EMBCEmbecta | $1.47 | +3% a year |
| PDEXPro DEX | $4.11 | +52% a year |
| TCMDTactile Systems Technology | $1.08 | +74% a year |
| MDXGMimedx | $0.04 | −81% a year |
| MOVMovado | $1.80 | +137% a year |
| KEQUKewaunee Scientific | $2.76 | −33% a year |
| IRMDIradimed | $1.79 | +10% a year |
| STAAStaar Surgical | $0.07 | |
| Peer median | $1.63 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Anika Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.